Related Experiment Videos
Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye
B A Kapteijn1, O E Nieweg, I Liem
1Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, The Netherlands.
Annals of Surgical Oncology
|March 1, 1997
Summary
Combining patent blue dye (PBD) with a gamma probe improves sentinel lymph node (SN) detection in melanoma patients to 99.5%, significantly outperforming PBD alone (84%). This enhances SN biopsy accuracy for patient selection.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Imaging
Background:
- Sentinel node (SN) biopsy is crucial for staging melanoma patients and guiding therapeutic lymphadenectomy.
- Accurate SN localization is essential for effective staging and treatment planning.
Purpose of the Study:
- To evaluate the combined efficacy of patent blue dye (PBD) and gamma probe detection of 99mTc-nanocolloid for SN localization in cutaneous melanoma.
- To compare the detection rates of PBD alone versus the combined method.
Main Methods:
- 110 patients with cutaneous melanoma underwent lymphoscintigraphy using 99mTc-nanocolloid.
- Patent blue dye (PBD) was injected prior to surgery.
- SNs were identified intraoperatively using both visual detection of blue coloration and gamma probe measurement of radioactivity.
Main Results:
- A total of 237 SNs were excised from 141 basins.
- Patent blue dye (PBD) alone identified 84% (200/237) of SNs.
- The gamma probe successfully localized the remaining 37 SNs not identified by PBD, achieving a combined detection rate of 99.5% (237/237).
- Tumor was found in the SN of 23 patients; three SNs were false-negative.
Conclusions:
- The combination of gamma probe and PBD significantly enhances SN identification rates in melanoma patients compared to PBD alone.
- This improved localization accuracy is vital for precise staging and appropriate patient management in melanoma.